Clinical trial · Interventional
Study of NK Combined With Chemotherapy for Advanced Solid Tumor
Study of Natural Killer Cell Combined With Chemotherapy for Advanced Solid Tumor
NCT04214730CI-TRIAL-00065096NKunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Combinations Natural Killer Cell (NK) With chemotherapy treatment may enhance the immune response and stop cancer cells from growing.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy | Drug | Chemotherapy | ALIAS |
| NK combined with Chemotherapy | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Combination of NK with chemotherapy group
- description
- Patients will receive NK treatments combined with Chemotherapy.
- interventionNames
- Combination Product: NK combined with Chemotherapy
- type
- ACTIVE_COMPARATOR
- label
- Chemotherapy group
- description
- Patients will only receive Chemotherapy.
- interventionNames
- Drug: Chemotherapy
Primary outcomes (1)
- measure
- Disease Control Rates (DCR)
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 10 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with treatment-refractory advanced solid cancer can not accept operation; 2. Age 10 to 90 years; 3. Eastern Cooperative Oncology Group (ECOG) score ≤ 2 points; 4. estimate survival \> 3 months; 5. Blood White Blood Cell(WBC)≥ 4×109/L, Hb ≥ 100g/L, Platelet Count (PLT)≥ 80×109/L; Alanine amino transferase (ALT) and aspartate amino transferase (AST)≤ 2 times of normal upper value; Serum Cr ≤ 2 normal upper value; 6. Without any other malignant disease; 7. With more than one scalable lesions; 8. Patients Voluntary attempt, and informed consent; 9. Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the preparative chemotherapy on the fetus. Exclusion Criteria: 1. Patients who do not conform to the inclusion criteria; 2. Patients with uncontrolled infection; underlying disease that was severe or life-threatening (such as uncontrolled brain metastasis ); 3. Patients who were pregnant or lactating; 4. ECOG perform status ≥ 2;4. 5. Other situations that the researchers considered unsuitable for this study (such as mental illness, drug abuse, etc.)
References
Publications (0)
Data not yet available
No reference posted for this study.